PE20020505A1 - QUINUCLIDINE GROUPS SUBSTITUTED WITH HETEROARYL FOR THE TREATMENT OF DISEASES - Google Patents
QUINUCLIDINE GROUPS SUBSTITUTED WITH HETEROARYL FOR THE TREATMENT OF DISEASESInfo
- Publication number
- PE20020505A1 PE20020505A1 PE2001000834A PE2001000834A PE20020505A1 PE 20020505 A1 PE20020505 A1 PE 20020505A1 PE 2001000834 A PE2001000834 A PE 2001000834A PE 2001000834 A PE2001000834 A PE 2001000834A PE 20020505 A1 PE20020505 A1 PE 20020505A1
- Authority
- PE
- Peru
- Prior art keywords
- cycloalkyl
- rent
- carboxamide
- oct
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA I DONDE R1 ES H, ALQUILO, CICLOALQUILO, ALQUILO HALOGENADO, ARILO; R2 ES H, ALQUILO, ALQUILO HALOGENADO, ALQUILO SUSTITUIDO, CICLOALQUILO, BENCILO, ENTRE OTROS; W ES EL GRUPO a ENTRE OTROS DONDE V E Y SON =N, =C(R5)-; Z ES =N, =CH- Y CON LA CONDICION DE QUE CUANDO V E Y SEAN AMBOS =C(R5)- Y Z ES =CH, SOLAMENTE UN =C(R5)- PUEDE SER =CH- Y CON LA CONDICION ADICIONAL DE QUE CUANDO U ES O, Y ES =C(R5)- Y Z ES =C(R5)-, V NO PUEDE SER =N-; R3 ES H, ALQUILO, CICLOALQUILO, HETEROCICLOALQUILO, ALQUILO HALOGENADO, CICLOALQUILO HALOGENADO, ENTRE OTROS; R5 ES H, ALQUILO, ALQUENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS N[(3R)-1-AZABICICLO[2.2.2]OCT-3-IL]-5-FENIL-TIOFEN-2-CARBOXAMIDA, N[(3R)-1-AZABICICLO[2.2.2]OCT-3-IL]-5-(4-CLOROFENIL)-TIOFEN-2-CARBOXAMIDA, N[(3R)-1-AZABICICLO[2.2.2]OCT-3-IL]-5-(3-CLOROFENIL)-TIOFEN-2-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS ACTUAN SOBRE LOS RECEPTORES DE LA ACETILCOLINA O7 NICOTINICOS Y REGULA LA ACTIVIDAD DEL SISTEMA NERVIOSO CENTRALREFERS TO COMPOUNDS OF FORMULA I WHERE R1 IS H, ALKYL, CYCLOALKYL, HALOGENATED ALKYL, ARYL; R2 IS H, RENT, HALOGENATED RENT, SUBSTITUTE RENT, CYCLOALKYL, BENZYL, AMONG OTHERS; W IS THE GROUP a AMONG OTHERS WHERE V E AND ARE = N, = C (R5) -; Z IS = N, = CH- AND WITH THE CONDITION THAT WHEN YOU SEE BOTH = C (R5) - YZ IS = CH, ONLY (R5) - CAN BE = CH- AND WITH THE ADDITIONAL CONDITION THAT WHEN U IS O, Y ES = C (R5) - YZ ES = C (R5) -, V CANNOT BE = N-; R3 IS H, ALKYL, CYCLOALKYL, HETERO CYCLOALKYL, HALOGENATED ALKYL, HALOGEN CYCLOALKYL, AMONG OTHERS; R5 IS H, RENT, ALKENYL, AMONG OTHERS. THE PREFERRED COMPOUNDS ARE N [(3R) -1-AZABICYCLE [2.2.2] OCT-3-IL] -5-PHENYL-THIOFEN-2-CARBOXAMIDE, N [(3R) -1-AZABICYCLE [2.2.2] OCT- 3-IL] -5- (4-CHLOROPHENYL) -THIOPHEN-2-CARBOXAMIDE, N [(3R) -1-AZABICYCLO [2.2.2] OCT-3-IL] -5- (3-CHLOROPHENYL) -THOFEN- 2-CARBOXAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THE MENTIONED COMPOUNDS ACT ON ACETYLCHOLINE O7 NICOTINES RECEPTORS AND REGULATES THE ACTIVITY OF THE CENTRAL NERVOUS SYSTEM
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22665200P | 2000-08-21 | 2000-08-21 | |
| US28483201P | 2001-04-19 | 2001-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020505A1 true PE20020505A1 (en) | 2002-06-12 |
Family
ID=26920741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000834A PE20020505A1 (en) | 2000-08-21 | 2001-08-21 | QUINUCLIDINE GROUPS SUBSTITUTED WITH HETEROARYL FOR THE TREATMENT OF DISEASES |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1311505A2 (en) |
| JP (1) | JP2004506734A (en) |
| AU (1) | AU2001282910A1 (en) |
| PE (1) | PE20020505A1 (en) |
| WO (1) | WO2002016355A2 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| SE0000540D0 (en) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| EP1463481A4 (en) | 2001-12-14 | 2008-06-25 | Targacept Inc | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS |
| DE10211415A1 (en) * | 2002-03-15 | 2003-09-25 | Bayer Ag | New azabicycloalkyl carboxylic acid N-biarylamides, are alpha-7-nicotinic acetylcholine receptor ligands useful for improving attention, concentration, learning and/or memory performance |
| DE10211416A1 (en) * | 2002-03-15 | 2003-09-25 | Bayer Ag | New azabicycloalkyl carboxylic acid N-arylamides, are alpha 7-nicotinic acetylcholine receptor ligands useful for improving attention, concentration, learning and/or memory performance |
| DE10234424A1 (en) * | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophene, benzofuran and indoleureas |
| WO2004052889A1 (en) * | 2002-12-06 | 2004-06-24 | Pharmacia & Upjohn Company Llc | Compounds as radioligands for the diagnosis of disease |
| BRPI0406834A (en) * | 2003-01-22 | 2005-12-27 | Pharmacia & Upjohn Co Llc | Treatment of disease with nach alfa-7 total receptor agonists |
| CA2539811A1 (en) | 2003-10-15 | 2005-04-28 | Targacept, Inc. | Azabicycyclic compounds for relieving pain and treating central nervous system disorders |
| SE0303075D0 (en) * | 2003-11-19 | 2003-11-19 | Astrazeneca Ab | 4-substituted imidazoles |
| SE0303076D0 (en) * | 2003-11-19 | 2003-11-19 | Astrazeneca Ab | 5-substituted imidazoles |
| MXPA06007026A (en) * | 2003-12-22 | 2006-08-31 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands. |
| KR20060123365A (en) * | 2003-12-22 | 2006-12-01 | 아스트라제네카 아베 | Nicotinic Acetylcholine Receptor Ligand |
| US7514450B2 (en) | 2004-05-19 | 2009-04-07 | Neurosearch A/S | Azabicyclic aryl derivatives |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| CN101248073A (en) | 2005-08-22 | 2008-08-20 | 塔加西普特公司 | Heteroaryl-substituted diazatricycloalkanes, methods for their preparation and applications |
| SA08290475B1 (en) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2S,3R)-N-(2-((3-pyrdinyl)methyl)-1-aza bicyclo[2,2,2]oct-3-yl)benzofuran-2-carboxamide, its new salt forms and methods of use |
| WO2009029632A1 (en) | 2007-08-27 | 2009-03-05 | Helicon Therapeutics, Inc. | Therapeutic isoxazole compounds |
| ES2362326T3 (en) | 2007-10-01 | 2011-07-01 | Comentis, Inc. | DERIVATIVES OF 1H-INDOL-3-CARBOXYLATE OF QUINUCLIDIN-4-ILMETILO AS LEGANDS OF THE ACETILCOLINE NICOTINIC RECEPTOR ALFA 7 FOR THE TREATMENT OF ALZHEIMER'S DISEASE. |
| WO2009098282A1 (en) * | 2008-02-06 | 2009-08-13 | Novasaid Ab | Low molecular weight 2,5-disubstituted thiophene derivatives and use thereof in therapy |
| BRPI0907570A2 (en) | 2008-02-13 | 2019-09-24 | Targacept Inc | alpha7 nicotinic agonists and antipsychotics |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| DK2678327T3 (en) * | 2011-02-23 | 2016-12-12 | Lupin Ltd | Heteroaryl derivatives which ALFA7 nAChR modulators |
| EP2729455B1 (en) | 2011-07-05 | 2016-09-14 | Lupin Limited | Biaryl derivatives as nachr modulators |
| WO2013161871A1 (en) * | 2012-04-25 | 2013-10-31 | 興和株式会社 | Thiophene derivative having tlr-inhibiting activity |
| WO2014069554A1 (en) * | 2012-10-31 | 2014-05-08 | 東レ株式会社 | Quinuclidine amide derivative and medicinal use of same |
| US20170166561A1 (en) | 2014-07-11 | 2017-06-15 | Alpharmagen, Llc | Quinuclidine compounds for modulating alpha7-nicotinic acetylcholine receptor activity |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863919A (en) * | 1988-02-01 | 1989-09-05 | A. H. Robins Company, Incorporated | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes |
| IT1228288B (en) * | 1989-01-09 | 1991-06-07 | Zambon Spa | COMPOUNDS WITH ANTI-SEROTONIN ACTIVITY |
| JPH04247081A (en) * | 1991-02-01 | 1992-09-03 | Takeda Chem Ind Ltd | 5-membered heterocyclic acid amide |
| SE9600683D0 (en) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| ATE254618T1 (en) * | 1997-05-30 | 2003-12-15 | Neurosearch As | SPIRO QUINUCLIDINE DERIVATIVES, THEIR PREPARATION AND USE |
| SE9904176D0 (en) * | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
| SE0000540D0 (en) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
-
2001
- 2001-08-17 JP JP2002521456A patent/JP2004506734A/en active Pending
- 2001-08-17 EP EP01961664A patent/EP1311505A2/en not_active Withdrawn
- 2001-08-17 AU AU2001282910A patent/AU2001282910A1/en not_active Abandoned
- 2001-08-17 WO PCT/US2001/022597 patent/WO2002016355A2/en not_active Ceased
- 2001-08-21 PE PE2001000834A patent/PE20020505A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001282910A1 (en) | 2002-03-04 |
| WO2002016355A2 (en) | 2002-02-28 |
| JP2004506734A (en) | 2004-03-04 |
| EP1311505A2 (en) | 2003-05-21 |
| WO2002016355A3 (en) | 2002-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020505A1 (en) | QUINUCLIDINE GROUPS SUBSTITUTED WITH HETEROARYL FOR THE TREATMENT OF DISEASES | |
| PE20020721A1 (en) | QUINUCLIDINE DERIVATIVES AS ANTIMUSCARINAL AGENTS M3 | |
| NL980008I1 (en) | Use of sertindole to treat schizophrenia. | |
| ES2139638T3 (en) | 1,4-DISPUTED PIPERAZINES FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM AND NEUROENDOCRINE DISEASES. | |
| AR012264A1 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION AND METHOD TO OBTAIN THE COMPOSITION TO PREVENT OR AVOID A DISEASE ASSOCIATED WITH UNDESIATED METALOPROTEASICAL ACTIVITY | |
| AR001332A1 (en) | New tachykinin antagonist compounds, process to obtain them and pharmaceutical compositions containing them. | |
| AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
| CO4900033A1 (en) | METALOPROTEASE INHIBITING COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| MX9307062A (en) | QUINUCLIDINE DERIVATIVE FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND THE CENTRAL NERVOUS SYSTEM. | |
| ES2084361T3 (en) | QUINUCLIDINE DERIVATIVES. | |
| TW200517109A (en) | Substituted pyridinones | |
| DK0937041T3 (en) | Use of a pharmaceutically suitable salt of (3R, 2'R) -3 - [(cyclopentyl-hydroxyphenylacetyl) oxyl] -1,1-dimethyl-pyrrolidinium for the preparation of a drug | |
| GR3019450T3 (en) | Azaheterocyclylmethyl-chromans as agents for the treatment of diseases of the central nervous system | |
| UY28496A1 (en) | BENCIMIDAZOLONE COMPOUNDS THAT HAVE AGENIST ACTIVITY OF THE RECEIVER 5-HT4 | |
| ATE286384T1 (en) | SUSTAINED RELEASE FORMULATION CONTAINING COLLAGEN AND GLYCOSAMINOGLYCAN | |
| UA27749C2 (en) | Substituted cyclopropylamino-1,3,5-triazines, enantiomers, racemic mixtures or non-toxic, pharmaceutically acceptable acid addition salts thereof possessing pharmacological activity and process for the preparation thereof | |
| PE20001037A1 (en) | HETEROCICLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | |
| ES2160648T3 (en) | DERIVATIVES OF PIRIDINE. | |
| ES2194918T3 (en) | TIAZOL AND TIADIAZOL COMPOUNDS AS BINDING DOPAMINE RECEIVER D3. | |
| ES2164889T3 (en) | SEMICARBAZONAS WITH ACTIVITY ON THE SNC AND PHARMACEUTICAL PREPARATIONS BASED ON THE SAME. | |
| PE20060656A1 (en) | IMIDAZO [1,2-a] PYRIDINYL COMPOUNDS AS MODULATORS OF CHEMOKINE ACTIVITY | |
| ES2164088T3 (en) | ANTAGONISTS OF THE SUBSTANCE P FOR THE TREATMENT OF EMESIS. | |
| EE03215B1 (en) | Single Reactor Preparation of 3-Quinolone Carboxylic Acid Derivatives | |
| ATE304373T1 (en) | NERVOUS PROTECTIVES | |
| ES2084339T3 (en) | TETRAHIDROPIRIDINAS AND HIDROXIPIPERIDINAS SUBSTITUTED USEFUL AS AGENTS FOR THE CENTRAL NERVOUS SYSTEM. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |